반응식
[Cl:1][C:2]1[CH:3]=[C:4]([CH:17]=[CH:18][CH:19]=1)[CH2:5][C:6]1[NH:7][C:8](=[O:16])[C:9]([C:14]#[N:15])=[C:10](SC)[N:11]=1.[CH3:20][C:21]1([CH3:27])[CH2:26][CH2:25][NH:24][CH2:23][CH2:22]1>>[CH3:20][C:21]1([CH3:27])[CH2:26][CH2:25][N:24]([C:10]2[N:11]=[C:6]([CH2:5][C:4]3[CH:17]=[CH:18][CH:19]=[C:2]([Cl:1])[CH:3]=3)[NH:7][C:8](=[O:16])[C:9]=2[C:14]#[N:15])[CH2:23][CH2:22]1참가 물질
3
실험 절차
In analogy to the preparation of Example 1, 150 mg (0.51 mmol) of 2-(3-chlorobenzyl)-4-(methylsulphanyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile are reacted with 582 mg (5.14 mmol) of 4,4-dimethylpiperidine to give 96 mg (52% of theory) of the title compound.
출처 및 근거
- ORD 기록
- ord-3a2af563e55642549d5e7367ca025bfe
- 출처 데이터셋
- uspto-grants-2012_01
- 특허 번호
- US08088769B2
연결된 노트
불러오는 중…